Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depression, Major Depressive Disorder
Interventions: AXS-05, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 43
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 39 more

Conditions: Depressive Disorder, Major, Metabolic Syndrome X
Interventions: Pioglitazone; Drug
Lead sponsor: Joseph Calabrese, MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depressive Disorder, Coronary Artery Disease
Interventions: Vortioxetine; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions: Health Care Management and Supported Rehabilitation; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 180 participants
Timeline: 2001 – 2006
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashua, New Hampshire

Conditions: Major Depression
Interventions: Not listed
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: tDCS; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder, Depression
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Depressive Disorder, Major
Interventions: No intervention; Other
Lead sponsor: Stanford University; Other
Eligibility: 9 Years to 15 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Stanford, California

Conditions: Major Depressive Disorder
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions: SPT-300, Placebo; Drug
Lead sponsor: Seaport Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Chino, California • Garden Grove, California • Glendale, California + 25 more

Conditions: Major Depressive Disorder
Interventions: Digital CBT, Waitlist; Device · Other
Lead sponsor: Big Health Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Treatment Resistant Depression, Major Depressive Disorder
Interventions: AXS-05 (dextromethorphan-bupropion); Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more

Conditions: Depressive Disorder, Major, Bipolar Depression, Suicidal Ideation
Interventions: Triple Chronotherapy, Treatment as Usual; Behavioral
Lead sponsor: Billings Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Billings, Montana

Conditions: Depression
Interventions: Parent Child Interaction Therapy-Emotion Development (PCIT-ED), Developmental Education Parenting Intervention (DEPI); Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 3 Years to 6 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Interventions: escitalopram; Drug
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Major Depressive Disorder, Bipolar Disorder, Schizophrenia
Interventions: Taking Action; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depressive Disorder, Major, Hepatitis C
Interventions: Cognitive behavioral treatment for depression; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Anaheim, California • Cerritos, California • Costa Mesa, California + 36 more

Conditions: Major Depressive Disorder (MDD)
Interventions: agomelatine, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 51
States / cities: Mesa, Arizona • Los Angeles, California • Oceanside, California + 42 more

Conditions: Major Depressive Disorder
Interventions: DVS-SR 50 mg, DVS-SR 100 mg, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 25
States / cities: Beverly Hills, California • Northridge, California • Farmington, Connecticut + 21 more

Conditions: Major Depressive Disorder (MDD)
Interventions: DT-101, Placebo; Drug
Lead sponsor: Draig Therapeutics Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Oceanside, California + 19 more

Conditions: Major Depressive Disorder
Interventions: NeuroStar TMS; Device
Lead sponsor: Neuronetics; Other
Eligibility: 18 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Chicago, Illinois • Baltimore, Maryland • Lincoln, Nebraska + 3 more

Conditions: Anhedonia, Major Depressive Disorder
Interventions: Placebo, NBI-1065846; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Depression in Adolescence, Rumination
Interventions: Mindfulness + fMRI Neurofeedback; Other
Lead sponsor: Columbia University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Search by objective public record fields.

A Trial of AXS-05 in Patients With Major Depressive Disorder

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People

Serum Markers as a Bioassay for Unipolar Depression

Adaptive tDCS for Treatment-Resistant MDD

Mechanism of Action of Transcranial Magnetic Stimulation

Mothers With a History of Depression and Their 10-14 Year Old Daughters

ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Rise Study for Depression

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

Triple Chronotherapy in Adolescents

Effectiveness of Parent-Child Interaction and Emotion Development Therapy in Treating Preschool Children With Depression

Escitalopram (Lexapro) for Depression MS or ALS

Taking Action for College Students

Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

Mindfulness-Based fMRI Neurofeedback for Depression